Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Nuclear Cardiology
Erschienen in: Journal of Nuclear Cardiology 6/2021

20.07.2020 | ORIGINAL ARTICLE

Coronary vasomotor dysfunction in cancer survivors treated with thoracic irradiation

verfasst von: John D. Groarke, MBBCh, MPH, Sanjay Divakaran, MD, Anju Nohria, MD, Joseph H. Killoran, PhD, Sharmila Dorbala, MD, MPH, Ruth M. Dunne, MBBCh, MPH, Jon Hainer, BS, Viviany R. Taqueti, MD, MPH, Ron Blankstein, MD, Harvey J. Mamon, MD, PhD, Marcelo F. Di Carli, MD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

We sought to test the hypothesis that thoracic radiation therapy (RT) is associated with impaired myocardial flow reserve (MFR), a measure of coronary vasomotor dysfunction.

Methods

We retrospectively studied thirty-five consecutive patients (71% female, mean ± standard deviation (SD) age: 66 ± 11 years) referred clinically for positron emission tomography/computed tomography (PET/CT) myocardial perfusion imaging at a median (interquartile range, IQR) interval of 4.3 (2.1, 9.7) years following RT for a variety of malignancies. Radiation dose-volume histograms were generated for the heart and coronary arteries for each patient.

Results

The median (IQR) of mean cardiac radiation doses was 12.0 (1.2, 24.2) Gray. There were significant inverse correlations between mean radiation dose and global MFR (MFRGlobal) and MFR in the left anterior descending artery territory (MFRLAD): Pearson’s correlation coefficient = − .37 (P = .03) and − .38 (P = .03), respectively. For every one Gray increase in mean cardiac radiation dose, there was a mean ± standard error decrease of .02 ± .01 in MFRGlobal (P = .04) and MFRLAD (P = .03) after adjustment.

Conclusions

In patients with a history of RT clinically referred for cardiac stress PET, we found an inverse correlation between mean cardiac radiation dose and coronary vasomotor function.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;366:2087-106.PubMed
2.
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987-98.PubMed
3.
Rehammar JC, Jensen MB, McGale P, Lorenzen EL, Taylor C, Darby SC, et al. Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977-2005. Radiother Oncol 2017;123:299-305.PubMedPubMedCentral
4.
Henson KE, Reulen RC, Winter DL, Bright CJ, Fidler MM, Frobisher C, et al. Cardiac mortality Among 200 000 five-year survivors of cancer diagnosed at 15 to 39 years of age: The teenage and young adult cancer survivor study. Circulation 2016;134:1519-31.PubMedPubMedCentral
5.
Speirs CK, DeWees TA, Rehman S, Molotievschi A, Velez MA, Mullen D, et al. Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer. J Thorac Oncol 2017;12:293-301.PubMed
6.
Dess RT, Sun Y, Matuszak MM, Sun G, Soni PD, Bazzi L, et al. Cardiac events after radiation therapy: Combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol 2017;35:1395-402.PubMedPubMedCentral
7.
Atkins KM, Rawal B, Chaunzwa TL, Lamba N, Bitterman DS, Williams CL, et al. Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer. J Am Coll Cardiol 2019;73:2976-87.PubMed
8.
Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011;117:412-8.PubMed
9.
Stewart FA, Hoving S, Russell NS. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat Res 2010;174:865-9.PubMed
10.
Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: A report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013;14:721-40.PubMed
11.
Darby SC, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, et al. Radiation-related heart disease: Current knowledge and future prospects. Int J Radiat Oncol Biol Phys 2010;76:656-65.PubMedPubMedCentral
12.
Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: Is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys 2007;67:10-8.PubMed
13.
van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 2016;34:235-43.PubMed
14.
Jacobse JN, Duane FK, Boekel NB, Schaapveld M, Hauptmann M, Hooning MJ et al. Radiation dose-response for risk of myocardial infarction in breast cancer survivors. Int J Radiat Oncol Biol Phys 2018.
15.
van den Bogaard VA, Ta BD, van der Schaaf A, Bouma AB, Middag AM, Bantema-Joppe EJ, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol 2017;35:1171-8.PubMedPubMedCentral
16.
Ziadi MC, Dekemp RA, Williams KA, Guo A, Chow BJ, Renaud JM, et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol 2011;58:740-8.PubMed
17.
Herzog BA, Husmann L, Valenta I, Gaemperli O, Siegrist PT, Tay FM, et al. Long-term prognostic value of 13 N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 2009;54:150-6.PubMed
18.
Naya M, Murthy VL, Foster CR, Gaber M, Klein J, Hainer J, et al. Prognostic interplay of coronary artery calcification and underlying vascular dysfunction in patients with suspected coronary artery disease. J Am Coll Cardiol 2013;61:2098-106.PubMedPubMedCentral
19.
Taqueti VR, Everett BM, Murthy VL, Gaber M, Foster CR, Hainer J, et al. Interaction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease. Circulation 2015;131:528-35.PubMed
20.
Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation 2011;124:2215-24.PubMedPubMedCentral
21.
Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation 2015;131:19-27.PubMed
22.
Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation 2012;126:1858-68.PubMedPubMedCentral
23.
Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Dorbala S, et al. Coronary vascular dysfunction and prognosis in patients with chronic kidney disease. JACC Cardiovasc imaging 2012;5:1025-34.PubMedPubMedCentral
24.
Bajaj NS, Osborne MT, Gupta A, Tavakkoli A, Bravo PE, Vita T, et al. Coronary microvascular dysfunction and cardiovascular risk in obese patients. J Am Coll Cardiol 2018;72:707-17.PubMedPubMedCentral
25.
Taqueti VR, Ridker PM. Inflammation, coronary flow reserve, and microvascular dysfunction: Moving beyond cardiac syndrome X. JACC Cardiovasc Imaging 2013;6:668-71.PubMedPubMedCentral
26.
Morise AP. Comparison of the Diamond-Forrester method and a new score to estimate the pretest probability of coronary disease before exercise testing. Am Heart J 1999;138:740-5.PubMed
27.
Moncayo VM, Garcia EV. Prompt-gamma compensation in Rb-82 myocardial perfusion 3D PET/CT: Effect on clinical practice. J Nucl Cardiol 2018;25:606-8.PubMed
28.
Schelbert HR, Beanlands R, Bengel F, Knuuti J, Dicarli M, Machac J, et al. PET myocardial perfusion and glucose metabolism imaging: Part 2-Guidelines for interpretation and reporting. J Nucl Cardiol 2003;10:557-71.PubMed
29.
Leslie WD, Tully SA, Yogendran MS, Ward LM, Nour KA, Metge CJ. Prognostic value of automated quantification of 99mTc-sestamibi myocardial perfusion imaging. J Nucl Med 2005;46:204-11.PubMed
30.
Chiles C, Duan F, Gladish GW, Ravenel JG, Baginski SG, Snyder BS, et al. Association of coronary artery calcification and mortality in the national lung screening trial: A comparison of three scoring methods. Radiology 2015;276:82-90.PubMed
31.
El Fakhri G, Sitek A, Guérin B, Kijewski MF, Di Carli MF, Moore SC. Quantitative dynamic cardiac 82Rb PET using generalized factor and compartment analyses. J Nucl Med 2005;46:1264-71.PubMed
32.
El Fakhri G, Kardan A, Sitek A, Dorbala S, Abi-Hatem N, Lahoud Y, et al. Reproducibility and accuracy of quantitative myocardial blood flow assessment with (82)Rb PET: Comparison with (13)N-ammonia PET. J Nucl Med 2009;50:1062-71.PubMed
33.
Gaya AM, Ashford RF. Cardiac complications of radiation therapy. Clin Oncol (R Coll Radiol) 2005;17:153-9.
34.
Schultz-Hector S. Radiation-induced heart disease: Review of experimental data on dose response and pathogenesis. Int J Radiat Biol 1992;61:149-60.PubMed
35.
Hayashi T, Kusunoki Y, Hakoda M, Morishita Y, Kubo Y, Maki M, et al. Radiation dose-dependent increases in inflammatory response markers in A-bomb survivors. Int J Radiat Biol 2003;79:129-36.PubMed
36.
Recio-Mayoral A, Rimoldi OE, Camici PG, Kaski JC. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovascular imaging 2013;6:660-7.PubMed
37.
Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014.
38.
Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997 2003. Radiation research 2012;178:AV146-72.
39.
Carr ZA, Land CE, Kleinerman RA, Weinstock RW, Stovall M, Griem ML, et al. Coronary heart disease after radiotherapy for peptic ulcer disease. Int J Radiat Oncol Biol Phys 2005;61:842-50.PubMed
40.
Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005;97:419-24.PubMed
41.
Azizova TV, Muirhead CR, Druzhinina MB, Grigoryeva ES, Vlasenko EV, Sumina MV, et al. Cardiovascular diseases in the cohort of workers first employed at Mayak PA in 1948-1958. Radiat Res 2010;174:155-68.PubMed
42.
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768-801.PubMed
43.
Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J 2018;39:840-9.PubMed
44.
van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, et al. Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines. Blood 2017;129:2257-65.PubMedPubMedCentral
45.
Ng A, Brock KK, Sharpe MB, Moseley JL, Craig T, Hodgson DC. Individualized 3D reconstruction of normal tissue dose for patients with long-term follow-up: A step toward understanding dose risk for late toxicity. Int J Radiat Oncol Biol Phys 2012;84:e557-63.PubMed
Metadaten
Titel
Coronary vasomotor dysfunction in cancer survivors treated with thoracic irradiation
verfasst von
John D. Groarke, MBBCh, MPH
Sanjay Divakaran, MD
Anju Nohria, MD
Joseph H. Killoran, PhD
Sharmila Dorbala, MD, MPH
Ruth M. Dunne, MBBCh, MPH
Jon Hainer, BS
Viviany R. Taqueti, MD, MPH
Ron Blankstein, MD
Harvey J. Mamon, MD, PhD
Marcelo F. Di Carli, MD
Publikationsdatum
20.07.2020
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 6/2021
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-020-02255-5

Weitere Artikel der Ausgabe 6/2021

Journal of Nuclear Cardiology 6/2021 Zur Ausgabe

EDITORIAL

Is what you see what you get?

Editorial

Evaluation of the impact of laboratory accreditation on downstream outcomes

EDITORIAL

Beware! Some crucial information is left unattended on our myocardial perfusion scans!

Review Article

Evaluation of cardiac allograft vasculopathy by positron emission tomography

EDITORIAL

Observations from stress testing in the troponin twilight zone

Editorial

Cardiac dysfunction in cancer survivors after thoracic irradiation: A necessary evil?

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise